Article

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Okairos, via dei Castelli Romani 22, 00040 Pomezia, Rome, Italy.
Science translational medicine (impact factor: 7.8). 01/2012; 4(115):115ra2. DOI:10.1126/scitranslmed.3002925 pp.115ra2
Source: PubMed

ABSTRACT Replication-defective adenovirus vectors based on human serotype 5 (Ad5) induce protective immune responses against diverse pathogens and cancer in animal models, as well as elicit robust and sustained cellular immunity in humans. However, most humans have neutralizing antibodies to Ad5, which can impair the immunological potency of such vaccines. Here, we show that rare serotypes of human adenoviruses, which should not be neutralized in most humans, are far less potent as vaccine vectors than Ad5 in mice and nonhuman primates, casting doubt on their potential efficacy in humans. To identify novel vaccine carriers suitable for vaccine delivery in humans, we isolated and sequenced more than 1000 adenovirus strains from chimpanzees (ChAd). Replication-defective vectors were generated from a subset of these ChAd serotypes and screened to determine whether they were neutralized by human sera and able to grow in human cell lines. We then ranked these ChAd vectors by immunological potency and found up to a thousandfold variation in potency for CD8+ T cell induction in mice. These ChAd vectors were safe and immunologically potent in phase 1 clinical trials, thereby validating our screening approach. These data suggest that the ChAd vectors developed here represent a large collection of non-cross-reactive, potent vectors that may be exploited for the development of new vaccines.

0 0
 · 
1 Bookmark
 · 
100 Views
  • Article: Multiple functions of human T cells generated by experimental malaria challenge.
    Stephen M Todryk, Michael Walther, Philip Bejon, Claire Hutchings, Fiona M Thompson, Britta C Urban, David W Porter, Adrian V S Hill
    [show abstract] [hide abstract]
    ABSTRACT: Protective immunity generated following malaria infection may be comprised of Ab or T cells against malaria Ag of different stages; however, the short-lived immunity that is observed suggests deficiency in immune memory or regulatory activity. In this study, cellular immune responses were investigated in individuals receiving Plasmodium falciparum sporozoite challenge by the natural (mosquito bite) route as part of a malaria vaccine efficacy trial. Parasitemia, monitored by blood film microscopy and PCR, was subsequently cleared with drugs. All individuals demonstrated stable IFN-gamma, IL-2 and IL-4 ex vivo ELISPOT effector responses against P. falciparum-infected RBC (iRBC) Ag, 28 and 90 days after challenge. However, infected RBC-specific central memory responses, as measured by IFN-gamma cultured ELISPOT, were low and unstable over time, despite CD4(+) T cells being highly proliferative by CFSE dilution, and showed an inverse relationship to parasite density. In support of the observation of poor memory, co-culture experiments showed reduced responses to common recall Ag, indicating malaria-specific regulatory activity. This activity could not be accounted for by the expression of IL-10, TGF-beta, FOXP3 or CTLA-4, but proliferating T cells expressed high levels of CD95, indicating a pro-apoptotic phenotype. Lastly, there was an inverse relationship between FOXP3 expression, when measured 10 days after challenge, and ex vivo IFN-gamma measured more than 100 days later. This study shows that malaria infection elicits specific Th1 and Th2 effector cells, but concomitant weak central memory and regulatory activity, which may help to explain the short-lived immunity observed.
    European Journal of Immunology 09/2009; 39(11):3042-51. · 5.10 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1000 adenovirus strains
 
CD8+ T cell induction
 
ChAd vectors
 
elicit robust
 
human adenoviruses
 
human cell lines
 
human serotype 5
 
humans
 
new vaccines
 
nonhuman primates
 
novel vaccine carriers suitable
 
phase 1 clinical trials
 
potent vectors
 
potential efficacy
 
Replication-defective adenovirus vectors
 
Replication-defective vectors
 
thousandfold variation
 
vaccine delivery
 
vaccine vectors
 
vaccines